Adjuvant formulation including low viscosity chitosan or chitosan derivatives
AssigneeMerck Sharp & Dohme Corp.
InventorsErica L. Strable, David S. Thiriot, Eman Alkurdi, Colleen M. Barr
Life of this patent
Estimating the term…
Abstract
The invention relates generally to the use of chitosan and chitosan derivatives as an adjuvant in a vaccine composition. More specifically, the invention relates to pharmaceutical compositions and formulations that include a low viscosity chitosan or a trimethyl chitosan.
Claims34
A pharmaceutical composition comprising an active biological ingredient (ABI), a chitosan or a chitosan derivative, and a pharmaceutically acceptable carrier.
25-28. (canceled)
(canceled)
A method of inducing an immune response to an antigen in a human patient comprising co-administering to the patient (a) a pharmaceutical composition comprising an ABI and (b) a chitosan or chitosan derivative.
A kit comprising:
- (a) a vaccine comprising an active biological ingredient (ABI);
- and
- (b) a chitosan or a chitosan derivative.
A method of inducing a neutralizing immune response against an antigen in a patient in need thereof comprising:
- administering to the patient a pharmaceutical composition comprising:
- a chitosan or chitosan derivative, and
- an active biological ingredient (ABI) comprising an antigen,
- whereby the administration of the pharmaceutical composition induces a neutralizing immune response against the antigen in the patient.
Dependencies are inferred from the claim text.